Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter April 13, 2018

Evaluation of the protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing BmAMA1 as vaccines against Babesia microti infection in hamster

Guanbo Wang, Longzheng Yu, Artemis Efstratiou, Paul Franck Adjou Moumouni, Mingming Liu, Huanping Guo, Yang Gao, Shinuo Cao, Mo Zhou, Jixu Li, Aaron Edmond Ringo and Xuenan Xuan
From the journal Acta Parasitologica

Abstract

In the present study, we have investigated the protective effect of a heterologous prime-boost strategy with priming plasmid DNA followed by recombinant adenovirus, both expressing BmAMA1, against Babesia microti infection. Four groups consisting of 3 hamsters per group were immunized with pBmAMA1/Ad5BmAMA1, pNull/Ad5BmAMA1, pBmAMA1/Ad5Null and pNull/Ad5Null, followed by challenge infection with B. microti. Our results showed that hamsters immunized with plasmid and adenovirus expressing BmAMA1 developed a robust IgG and IgG2a antibody response against BmAMA1, suggesting the DNA vaccine or viral vector vaccine tend to induce a Th1-biased response. Compared to the control hamsters, the hamsters vaccinated either with the prime-boost strategy or one of the two “vaccines” exhibited no significant protection against B. microti challenge. Although a slight difference in terms of parasitemia and hematocrit values at days 14–16 post challenge infection was observed, no other statistical difference was detected. Our results indicate that the prime-boost vaccination strategy of injection of plasmid and adenovirus expressing BmAMA1 is not efficient in protecting against B. microti infection.

Acknowledgements

This study was supported by a Grant-in-Aid for Scientific Research, from the Ministry of Education, Culture, Sports, Science of Technology of Japan.

References

Mountford A.P., Fisher A., Wilson R.A., 1994. The profile of lgCl and IgC2a antibody responses in mice exposed to Schistosoma mansoni. Parasite Immunology, 16, 521–52710.1111/j.1365-3024.1994.tb00306.xSearch in Google Scholar PubMed

Anderson R.J., Schneider J., 2007. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 25, 24–34. 10.1016/j.vaccine.2007.05.030Search in Google Scholar PubMed

Caetano B.C., Bruña-romero O., Fux, B., Mendes E.A., Penido M.L.O., Gazzinelli R.T., 2006. Vaccination with Replication-Deficient Recombinant Adenoviruses Encoding the Main Surface Antigens of Toxoplasma gondii Induces Immune Response and Protection Against Infection in Mice. Human Gene Therapy 17, 415–42610.1089/hum.2006.17.415Search in Google Scholar PubMed

Campos-Neto A., 2005. What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery? Brazilian Journal of Medical and Biological Research, 38, 979–98410.1590/S0100-879X2005000700001Search in Google Scholar

Dunachie S.J., Hill A.V.S., 2003. Review Prime-boost strategies for malaria vaccine development. The Journal of Experimental Biology, 206, 3771–3779. 10.1242/jeb.00642Search in Google Scholar PubMed

Dutta S., Sullivan J.S., Grady K.K., Haynes J.D., Komisar J., Adrian H., et al., 2009. High Antibody Titer against Apical Membrane Antigen-1 Is Required to Protect against Malaria in the Aotus Model PLoS One 4, e8138. 10.1371/journal.pone.0008138Search in Google Scholar PubMed PubMed Central

Harvey K.L., Yap A., Gilson P.R., Cowman A.F., Crabb B.S., 2014. Insights and controversies into the role of the key apicomplexan invasion ligand, Apical Membrane Antigen 1. International Journal for Parasitology, 44, 853–857. 10.1016/j.ijpara.2014.08.001Search in Google Scholar PubMed

Hildebrandt A., Hunfeld K.P., Baier M., Krumbholz A., Sachse S., Lorenzen T., et al., 2007. First confirmed autochthonous case of human Babesia microti infection in Europe. European Journal of Clinical Microbiology & Infectious Diseases. 26, 595–601. 10.1007/s10096-007-0333-1Search in Google Scholar PubMed

Homer M.J., Aguilar-Delfin I., Telford S.R., Krause P.J., Persing D.H., 2000. Babesiosis. Clinical Microbiology Reviews, 13, 451–69. 10.1128/CMR.13.3.451-469.2000.Search in Google Scholar PubMed

Igarashi I., Suzuki R., Waki S., Tagawa Y.-I., Seng S., Tum S., et al., 1999. Roles of CD4+ T Cells and Gamma Interferon in Protective Immunity against Babesia microti Infection in Mice. Infection and Immunity. 67, 4143–414810.1128/IAI.67.8.4143-4148.1999Search in Google Scholar PubMed PubMed Central

Indresh K.S., Margaret A.L., 2013. Gene Vaccines. Ann. Annals of Internal Medicine, 138, 550–55910.7326/0003-4819-138-7-200304010-00011Search in Google Scholar

Kochan G., Gherardi M.M., Esteban M., Pe E., 2006. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes and Infection, 8, 810–822. 10.1016/j.micinf.2005.10.004Search in Google Scholar PubMed

Krause P.J., Gewurz B.E., Hill D., Marty F.M., Vannier E., Foppa I.M., et al., 2008. Persistent and relapsing babesiosis in immunocompromised patients. Clinical Infectious Diseases, 46, 370–376. 10.1086/525852Search in Google Scholar

Kumar S., Gubernot D.M., Nakhasi H.L., Mied P.A., Asher D.M., Epstein J.S., 2009. Transfusion-transmitted babesiosis in the United States: Summary of a workshop. Transfusion, 49, 2759–2771. 10.1111/j.1537-2995.2009.02429.xSearch in Google Scholar PubMed

Liu M.A., Ulmer J.B., 2005. Human Clinical Trials of Plasmid DNA Vaccines. Advances in Genetics. 55, 25–40. 10.1016/S0065–2660(05)55002-8Search in Google Scholar PubMed

Marathe A, Tripathi J, Handa V, Date V. 2005. Human babesiosis – A case report. Indian Journal of Medical Microbiology, 23, 267–26910.1016/S0255-0857(21)02536-6Search in Google Scholar PubMed

Moitra P., Zheng H., Anantharaman V., Banerjee R., Takeda K., Kozakai Y., et al. 2015. Expression, purification, and biological characterization of Babesia microti apical membrane antigen 1. Infection and Immunity, 83, 3890–3901. 10.1128/IAI.00168-15Search in Google Scholar PubMed

Ramshaw I.A., Ramsay A.J., 2000. The prime-boost strategy: exciting prospects for improved vaccination. Immunology Today, 2110.1016/S0167-5699(00)01612-1Search in Google Scholar

Reyes-Sandoval A., John T., Todryk S.M., 2007. Viral vector vaccines make memory T cells against malaria. Immunology 121, 158–165. 10.1111/j.l365-2567.2006.02552.xSearch in Google Scholar PubMed

Stowers A.W., Kennedy M.C., Keegan B.P., Saul A., Long C.A., Miller L.H., Mmun I.N.I., 2002. Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria. Infection and Immunity 86, 6961–6967. 10.1128/IAI.70.12.6961Search in Google Scholar

Takeda A., Igarashi H., Nakamura H., Kano M., Iida A., Hirata T., et al., 2003. Protective Efficacy of an AIDS Vaccine, a Single DNA Priming Followed by a Single Booster with a Recombinant Replication-Defective Sendai Virus Vector, in a Macaque AIDS Model. Journal of Virology 92, 9710–9715. 10.1128/JVI.77.17.9710Search in Google Scholar

Vannier E., Gewurz B.E., Krause P.J., 2008. Human Babesiosis. Infectious Disease Clinics of North America 22. 10.1016/j.idc.2008.03.010Search in Google Scholar PubMed PubMed Central

Wang G., Efstratiou A., Franck P., Moumouni A., Liu M., 2017. Experimental Parasitology Expression of truncated Babesia microti apical membrane protein 1 and rhoptry neck protein 2 and evaluation of their protective efficacy. Experimental Parasitology. 172, 5–11. 10.1016/j.exppara.2016.11.001Search in Google Scholar PubMed

Woodland D.L., 2004. Jump-starting the immune system : prime – boosting comes of age. Trends in Immunology, 25. 10.1016/j.it.2003.11.009Search in Google Scholar PubMed

Yu L., Yamagishi J., Zhang S., Jin C., Oluga G., 2012. Parasitology International Protective effect of a prime-boost strategy with plasmid DNA followed by recombinant adenovirus expressing TgAMA1 as vaccines against Toxoplasma gondii infection in mice. Parasitology International, 61, 481–486. 10.1016/j.parint.2012.04.001Search in Google Scholar PubMed

Zhang G., Huang X., Boldbaatar D., Battur B., 2010. Construction of Neospora caninum stably expressing TgSAG1 and evaluation of its protective effects against Toxoplasma gondii infection in mice. Vaccine, 28, 7243–7247. 10.1016/j.vaccine.2010.08.096Search in Google Scholar PubMed

Received: 2017-6-30
Revised: 2018-2-10
Accepted: 2018-3-5
Published Online: 2018-4-13
Published in Print: 2018-6-26

© 2018 W. Stefański Institute of Parasitology, PAS